ATI RN
ATI Pathophysiology Final Exam
1. A teacher in a preschool is diagnosed with giardiasis. Which of the following medications will be administered to treat the diarrhea and abdominal distention?
- A. Sulfasalazine (Azulfidine)
- B. Metronidazole (Flagyl)
- C. Trimethoprim–sulfamethoxazole (Bactrim)
- D. Doxycycline (Vibramycin)
Correct answer: B
Rationale: The correct answer is B. Metronidazole (Flagyl) is the drug of choice for treating giardiasis, which is a common cause of diarrhea and abdominal distention. Sulfasalazine (Choice A) is used to treat inflammatory bowel disease. Trimethoprim–sulfamethoxazole (Choice C) is commonly used for urinary tract infections and Pneumocystis jirovecii pneumonia. Doxycycline (Choice D) is commonly used to treat various bacterial infections but is not the first-line treatment for giardiasis.
2. A 50-year-old female was diagnosed with sideroblastic anemia. Which of the following assessment findings would most likely occur?
- A. Bronze-colored skin
- B. Decreased iron
- C. Normochromic erythrocytes
- D. Aplastic bone marrow
Correct answer: A
Rationale: The correct answer is A: 'Bronze-colored skin.' Sideroblastic anemia is characterized by excess iron deposition, leading to bronze-colored skin. This occurs due to the abnormal accumulation of iron in tissues. Choices B, C, and D are incorrect because sideroblastic anemia does not typically present with decreased iron levels, normochromic erythrocytes, or aplastic bone marrow.
3. A group of prison inmates developed tuberculosis following exposure to an infected inmate. On examination, tissues were soft and granular (like clumped cheese). Which of the following is the most likely cause?
- A. Coagulative necrosis
- B. Liquefactive necrosis
- C. Caseous necrosis
- D. Autonecrosis
Correct answer: C
Rationale: The correct answer is C. Caseous necrosis is characteristic of tuberculosis, where the tissue has a soft, cheese-like appearance. Coagulative necrosis involves protein denaturation, liquefactive necrosis is seen in brain infarcts and abscesses, and autonecrosis is not a recognized term in pathology, making them incorrect choices in this scenario.
4. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary mechanism of action for this medication?
- A. Raloxifene decreases bone resorption, which helps to maintain or increase bone density.
- B. Raloxifene increases calcium absorption in the intestines, which helps build stronger bones.
- C. Raloxifene stimulates new bone formation by increasing osteoblast activity.
- D. Raloxifene decreases calcium excretion by the kidneys, helping to maintain bone density.
Correct answer: A
Rationale: Raloxifene decreases bone resorption, which helps to maintain or increase bone density, making it effective in the prevention and treatment of osteoporosis.
5. A nurse is teaching a patient about the use of raloxifene (Evista) for the prevention of osteoporosis. What is the primary therapeutic action of this medication?
- A. It decreases the absorption of calcium from the intestines.
- B. It decreases bone resorption and increases bone density.
- C. It increases the excretion of calcium through the kidneys.
- D. It stimulates the formation of new bone.
Correct answer: B
Rationale: The correct answer is B. Raloxifene, a selective estrogen receptor modulator (SERM), works by decreasing bone resorption and increasing bone density. This action helps in preventing osteoporosis by maintaining bone strength. Choice A is incorrect as raloxifene does not affect the absorption of calcium from the intestines. Choice C is incorrect as raloxifene does not increase the excretion of calcium through the kidneys. Choice D is incorrect as raloxifene does not directly stimulate the formation of new bone; instead, it primarily works by reducing bone loss.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 50,000 Questions with answers
- All ATI courses Coverage
- 30 days access @ $69.99
ATI RN Premium
$149.99/ 90 days
- 50,000 Questions with answers
- All ATI courses Coverage
- 30 days access @ $149.99